AstraZeneca - Latest News and Investment Deals
AZN
AstraZeneca is a global science-led biopharmaceutical company that develops innovative medicines used by patients worldwide. It focuses on research-based discovery and development across multiple therapy areas, including oncology, cardiovascular, renal and metabolism, respiratory and immunology, vaccines, and rare diseases. The company emphasizes scientific collaboration and translational medicine to deliver targeted therapies and improve global health. Headquartered with a strong presence in the UK and collaborating worldwide, AstraZeneca operates through a global network of R&D centers and manufacturing facilities.
Innate Pharma to Participate in the Kempen Life Sciences Conference
Biotech in 2025: A Retrospective
Dizal Breaks New Ground for EGFR Drugs in Lung Cancer
NYAG Takes Action Against Public Company for Approving Insider 10b5-1 Plan
TerraPower Commits $450M to Build Radioisotope Production Plant
Breast Cancer Treatments Heat Up: Six Therapies Poised to Transform Patient Outcomes
Q3 Results Today Live: M&M, Divi’s Lab, Ashok Leyland, Lenskart, LG Electronics, Godrej, Patanjali Foods, AstraZeneca to Announce Q3 Results, Titan, Apollo Hospitals, Britannia Shares Gain, P N Gadgil & Grasim Shares in Red
AstraZeneca and Joshua Jackson Partner to Encourage Fans to Get Body Checked Against Cancer
AstraZeneca CEO Hails NHS Drug Price Deal but Keeps Pause on £200m UK Investment
Hacker Group LAPSUS$ Claims Alleged AstraZeneca Data Breach
Apple's Expanding Enterprise Footprint to Boost Sales: What's Ahead?
AstraZeneca Leads Big Pharma’s AI Clinical Trials Revolution with Real-World Patient Impact
HER2’s Digital Rebirth Is Unlocking the Full Potential of ADCs
EU Starts Review of First-Line Enhertu for Breast Cancer
Lipocine's Postpartum Depression Drug Fails; AstraZeneca Claims Liver Cancer Win
Highest Quarterly Hike Percentage Since 2019
The Top 10 PharmTech Videos of 2025
Merck to Acquire Terns Pharmaceuticals for $6.7 B, Accelerating M&A Ahead of Keytruda Patent Expiry
Proteasomes: A Novel Approach to Target the Immune System
TrumpRx Delayed Amid Potential Anti-Kickback Concerns
FDA Knocks Back AstraZeneca's Self-Injected Lupus Drug
9 Companies Hiring Now in Pennsylvania
Proliferating Patents, Lawsuits Stave Off Pharmas’ Generic Competitors
AbbVie, AstraZeneca Lose Appeal in Louisiana 340B Contract Pharmacy Fight
Rethinking Vaccine Production Platforms for Future Pandemics
Lilly Strikes Again, Buying CAR-T Firm Orna for $2.4bn
Facing Talent Crunch, Radiopharma Field Casts a Wide Net
AZ Signals All-In on Obesity via CSPC Deal for $1.2B up Front
Chinese-Owned Syngenta to Build New £100m Bioscience Hub in UK
New York Sues Ex-Emergent CEO over Insider Trading During Vaccine Manufacturing Struggle
Lynx Analytics Introduces Lumen, an Agentic AI Framework to Improve Decision-Making in Life Sciences
AstraZeneca’s Path to $80B by 2030 Paved With ADCs, Cell Therapies, Near-Term Product Launches
Ionis Paves Its Own Path as Initial Tryngolza Launch Defies Expectations
Ex-Novartis CMO John Tsai Joins Daiichi Sankyo
AstraZeneca Bets on In-House AI to Speed up Oncology Research
12 Most Profitable Blue Chip Stocks to Invest In Now
Women in STEM: Inspiration From Innovators in Pharma
Stocks Making the Biggest Moves Midday: Brown-Forman, Entergy, Meta Platforms, Carnival, Argan & More
The $500,000 Portfolio To Potentially Pay All Your Bills
Lung Cancer Trial to Proceed After FDA Releases Hold on Merck, Daiichi’s ADC
Former Emergent CEO Hit With Insider Trading Lawsuit
The Most Innovative Artificial Intelligence Companies of 2026
A Radical New Way to Alkylate Aromatic Rings
Twenty-Two Genes Could Hike Risk for Long-Term Health Issues After Epstein-Barr Infection
JCE: Large-Cap Equity Fund With Call Options, 8.15% Yield, And 5.7% Discount
Eikon Prices Its IPO, Seeking to Raise $318m
White House’s Online Service for Drug Sales Debuts with Limited Impact on Prices
FFA Equity Fund With Call-Overlay, 7.27% Yield, 10% Discount, And Decent Growth
Syneron Bio Raises $150M for Peptide Drug Platform
Eikon, a High-Profile Startup Led by Merck Vets, Seeks an IPO
AstraZeneca Acquires FibroGen China From Kyntra Bio
Kyntra Bio Completes Sale of FibroGen China to AstraZeneca
AstraZeneca Pays $630M to Acquire Full Control of AbelZeta's CAR‑T Therapy C‑CAR031
AstraZeneca Signs $1.2B Upfront Deal with CSPC for Obesity Assets
Syneron Bio Closes $150M Series B Funding Round
